Biosurveillance

Europe Point-of-Care, Biosensors and Rapid Diagnostics Conference 2023: From Novel Technologies to Regulatory Approval (Rotterdam, Netherlands - June 19-20, 2023) - ResearchAndMarkets.com

Retrieved on:

Wednesday, May 24, 2023

Health, Other Health, Engineering, Biosensor, Pandemic, Chemistry, Biosurveillance, Biology, POC, Imperial College London, Medical device, Vaccine

The "Point-of-Care, Biosensors and Rapid Diagnostics Europe 2023" training has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Point-of-Care, Biosensors and Rapid Diagnostics Europe 2023" training has been added to ResearchAndMarkets.com's offering.
This conference will provide an overview of the point-of-care (POC) testing landscape, from novel technologies to regulatory approval.
Emphasis will be placed on mobile diagnostics platforms and convergence with microfluidics-based and lab-on-a-chip approaches.
Next Generation Technologies for Pathogen Detection: Pandemics and Biosurveillance
Rapid Biodetection of Pathogens and Threat Identification: Pandemics and Biosurveillance
Professor of Biomedical Sensors Engineering, Imperial College London
Head of Division Microfluidic Platforms, Hahn-Schickard-Gesellschaft fur Angewandte Forschung eV

XWELL, Inc. Reports Third Quarter 2022 Results

Retrieved on:

Thursday, November 10, 2022

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL), a leading global health and wellness holding company, today reported results for the third quarter ending September 30, 2022.

Key Points:

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL), a leading global health and wellness holding company, today reported results for the third quarter ending September 30, 2022.
Cost of sales decreased to $9.3 million in the third quarter of 2022 from $13.7 million in the prior year third quarter, primarily as a result of the Company closing underperforming XpresCheck locations during the quarter.
Loss from operations was $7.65 million in the third quarter of 2022 compared to income from operations of $7.1 million in the prior year third quarter.
Net loss attributable to common shareholders was $7.2 million in the third quarter of 2022 compared to net income attributable to common shareholders of $5.6 million in the prior year third quarter.

Parsons Supporting U.S. Army Chemical and Biological Defense

Retrieved on:

Tuesday, September 20, 2022

The 10-year IDIQ, a multiple award contract with a program ceiling value of $869 million, will support the U.S. Army by providing acquisition life-cycle chemical and biological defense research, development, test, and evaluation support.

Key Points:

The 10-year IDIQ, a multiple award contract with a program ceiling value of $869 million, will support the U.S. Army by providing acquisition life-cycle chemical and biological defense research, development, test, and evaluation support.
We stand ready to support DEVCOM CBC as they deliver on their vision of providing innovative chemical and biological defense capabilities to advance national security and global combat operations, said Jon Moretta, president of Parsons engineered systems business unit.
STEPSS technical support tasks may include research, development, test, and evaluation; engineering, system acquisition, and engineering system development; and chemical, biological demilitarization operations.
Parsons biosurveillance and environmental sector is a mission-oriented group of experts, technology, and products focused on keeping humans healthy and safe from known and emerging biological threats, chemical contaminants, and other hazards.

Rancho Biosciences Wins NINDS NeuroBioBank Award to Integrate Neuropathological Data

Retrieved on:

Tuesday, August 30, 2022

SAN DIEGO, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Rancho Biosciences, the leading company in the field of life science data curation and data services, is pleased to announce they have been awarded a contract with Digital Infuzion, Inc., in support of the National Institute of Neurological Disorders and Stroke (NINDS) to curate and integrate data and metadata associated with the NIH NeuroBioBank (https://neurobiobank.nih.gov/).

Key Points:

SAN DIEGO, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Rancho Biosciences, the leading company in the field of life science data curation and data services, is pleased to announce they have been awarded a contract with Digital Infuzion, Inc., in support of the National Institute of Neurological Disorders and Stroke (NINDS) to curate and integrate data and metadata associated with the NIH NeuroBioBank (https://neurobiobank.nih.gov/).
The goal of this award is to make all this data compliant with FAIR data principles, which means that this data will meet the principles of findability, accessibility, interoperability, and reusability.
"Leveraging this vast public data resource supports our mission to save lives through data.The more data available to scientists, the better chance they have of making new discoveries and getting closer to cures," said Julie Bryant, CEO of Rancho BioSciences.
"We are grateful for the opportunity to be a part of the neurodegenerative data community and make a difference."

XpresSpa Group Reports Second Quarter 2022 Results

Retrieved on:

Monday, August 15, 2022

ET Today

Key Points:

ET Today
NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- XpresSpa Group, Inc. (Nasdaq: XSPA), a travel health and wellness company, today reported that it has filed financial results on Form 10-Q for the second quarter ending June 30, 2022.
This is the first of 5 new XpresSpa locations expected to open at Istanbul Airport by the end of 2022.
Cost of sales increased to $12.4 million from $7.7 million in the prior year second quarter primarily due to the increased costs to operate the XpresCheck locations, and the reopening of certain XpresSpa locations that were temporarily closed during the second quarter of 2021.
Net loss attributable to common shareholders was $7.9 million compared to $4.5 million in the prior year second quarter.

Ginkgo Bioworks and XpresCheck Receive Award to Expand CDC's Traveler-Based SARS-CoV-2 Genomic Surveillance Program In U.S. Airports

Retrieved on:

Monday, August 15, 2022

BOSTON and NEW YORK, Aug. 15, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) and XpresSpa Group, Inc. (Nasdaq: XSPA) announced they will continue to support the Centers for Disease Control and Prevention's (CDC's) traveler-based SARS-CoV-2 genomic surveillance program through a new contract awarded August 12, 2022. The partnership is expected to support public health and biosecurity services totaling approximately $16 million, with an overall potential to exceed $61 million based on CDC program options and public health priorities. As COVID-19 sublineages and other biological threats continue to emerge, the partners plan to expand the program footprint and incorporate innovative modalities and offerings, such as monitoring of wastewater from aircraft lavatories.

Key Points:

Currently, international travelers arriving at these airports from select countries can enroll in the program on a voluntary basis and be sampled for SARS-CoV-2 for pathogen surveillance purposes.
Ginkgo is building a platform to enable customers to program cells as easily as we can program computers.
XpresCheck is a leading provider of Covid-19 screening and diagnostic testing with 15 locations in 12 domestic airports.
XpresCheck is also partnered with CDC and Concentric by Ginkgo, conducting biosurveillance monitoring in its airport locations to identify existing and new SARS-CoV-2 variants.

Parsons Supporting U.S. Defense Health Agency On $10 Billion Omnibus IV Contract

Retrieved on:

Thursday, June 16, 2022

The $10 billion ceiling value Omnibus IV is a five-year multiple-award indefinite delivery/indefinite quantity contract with one five-year option period.

Key Points:

The $10 billion ceiling value Omnibus IV is a five-year multiple-award indefinite delivery/indefinite quantity contract with one five-year option period.
The Parsons team stands ready to deliver on DHAs mission of providing our countrys military health providers cutting-edge tools to deliver optimal care to service members, said Jon Moretta, president, engineered systems for Parsons.
Our biosurveillance and environmental services group offers a broad spectrum of innovative technical and support capabilities that will help maximize DHAs investment in force readiness, health, and resilience.
The Omnibus IV Military Medical Research and Development contract is a continuation of successful past government investments focused on the discovery and integration of medical innovations and material solutions to continually enhance force health readiness, resilience, and rehabilitation.

Point-of-Care, Biosensors and Mobile Diagnostics Conference Europe 2022: Overview of POC Testing Landscape, from Novel Technologies to Regulatory Approval - Rotterdam, Netherlands - June 21-22, 2022

Retrieved on:

Thursday, May 26, 2022

Biology, Chemistry, Solution, Industry, Biosensor, Pandemic, POC, Technology, Medical device, Vaccine, Biosurveillance

DUBLIN, May 26, 2022 /PRNewswire/ -- The "Point-of-Care, Biosensors and Mobile Diagnostics Europe 2022" conference has been added to ResearchAndMarkets.com's offering.

Key Points:

DUBLIN, May 26, 2022 /PRNewswire/ -- The "Point-of-Care, Biosensors and Mobile Diagnostics Europe 2022" conference has been added to ResearchAndMarkets.com's offering.
This conference will provide an overview of the point-of-care (POC) testing landscape, from novel technologies to regulatory approval.
Emphasis will be placed on mobile diagnostics platforms and convergence with microfluidics-based and lab-on-a-chip approaches.
Next Generation Technologies for Pathogen Detection: Pandemics and Biosurveillance
Rapid Biodetection of Pathogens and Threat Identification: Pandemics and Biosurveillance

CED Report: To Better Prepare for the Next Public Health Crisis, Government and Business Will Need Closer Collaboration

Retrieved on:

Tuesday, May 24, 2022

The overriding theme of the study is the importance of close public-private collaboration at all levels for dealing with public health crises.

Key Points:

The overriding theme of the study is the importance of close public-private collaboration at all levels for dealing with public health crises.
"Hard experience has taught us how inextricably linked the public and private sectors are during a national health emergency.
Cost-responsible consumer choice among competing private health care plans will drive the system toward quality, affordable health care for all.
Business should embrace its role as a trusted source of information for employees during a public health crisis.

XpresSpa Group Reports First Quarter 2022 Results

Retrieved on:

Monday, May 16, 2022

Repurchased $11.1 Million of Shares During the First Quarter 2022, Intends to Complete Remaining Repurchase Authorizationas Opportunities Arise

Key Points:

Repurchased $11.1 Million of Shares During the First Quarter 2022, Intends to Complete Remaining Repurchase Authorizationas Opportunities Arise
NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- XpresSpa Group, Inc. (Nasdaq: XSPA), a travel health and wellness company, today reported that it has filed financial results on Form 10-Q for the first quarter ending March 31, 2022.
Scott Milford, XpresSpa Group CEO, stated, The foundation for the future of our company is built on four strategic imperatives.
During the first quarter, we recognized $1.4 million of revenue related to this contract with the remaining $2.6 million of the contract expected to be recognized in the second quarter.
While a decline in the first quarter relative to the fourth quarter last year was not surprising, as the first quarter is typically the weakest quarter in terms of airport traffic, the decrease was faster than projected.